(Q35571246)

8 August 2017

1 reference

title

Oesophageal cancer: new developments in systemic therapy (English)

1 reference

8 August 2017

David H Ilson

1

1 reference

8 August 2017

publication date

1 December 2003

1 reference

8 August 2017

published in

Cancer Treatment Reviews

1 reference

8 August 2017

volume

29

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

525-532

1 reference

8 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Gastroesophageal reflux disease and Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Surgical therapy of oesophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Nonoperative therapy for squamous-cell cancer of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900104-X

7 January 2021

10.1016/S0305-7372(03)00104-X

Identifiers

DOI

1 reference

8 August 2017

1 reference